Two Northwestern Medicine studies are improving the understanding of epigenetic mechanisms in cancer development and progression, and identifying novel cancer driver genes that may help identify patients who will benefit from immunotherapy.
Northwestern Medicine investigators have discovered that oncogenes contain specific epigenetic markers called broad genic repression domains, which could help identify potential therapeutic targets for cancer treatment.
Maxwell Edmonds, a third-year medical student in the Medical Scientist Training Program (MSTP), recently defended his doctoral thesis on generating testicular organoids and looks back on his Feinberg journey so far.
A new study found that Black men with metastatic prostate cancer were more likely to have tumor mutations than white or Asian men, highlighting the significance genetic drivers have in increasing one’s risk for developing aggressive prostate cancer.
Inhibiting an epigenetic regulator called DOT1L could be a key to slowing treatment-resistant prostate cancer, according to a recent Northwestern Medicine study.
Sarki Abdulkadir, MD, PhD, has been named the winner of the 2020 Tripartite Legacy Faculty Prize in Translational Science and Education for his work investigating the molecular pathways that drive prostate cancer.
Northwestern neuroscientists and engineers have developed a tiny, implantable device that has potential to help people with bladder problems.
Men with inflammatory bowel disease have four to five times higher risk of prostate cancer, according to a new 20-year study.
Armed with a prestigious new grant, investigators prepare to rapidly translate scientific breakthroughs into better brain tumor therapies. Read the story in Northwestern Medicine magazine.
In a recent clinical trial, a drug called apalutamide added to standard therapy slowed cancer progression in men with prostate cancer, while maintaining quality of life.